54 related articles for article (PubMed ID: 26971738)
1. Het cytochroom P450 enzymsysteem: wat is de relevantie voor de praktijk? Deel II, interacties.
Touw DJ; Verhoeven WM; Noten JB
Acta Neuropsychiatr; 1998 Sep; 10(3):58-62. PubMed ID: 26971738
[TBL] [Abstract][Full Text] [Related]
2. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.
Shulman RW; Ozdemir V
Can J Psychiatry; 1997 Jun; 42 Suppl 1():4S-9S. PubMed ID: 9220124
[TBL] [Abstract][Full Text] [Related]
3. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.
Ma JD; Nafziger AN; Bertino JS
J Clin Pharmacol; 2004 May; 44(5):447-56. PubMed ID: 15102864
[TBL] [Abstract][Full Text] [Related]
5. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
[TBL] [Abstract][Full Text] [Related]
6. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation.
Akutsu T; Kobayashi K; Sakurada K; Ikegaya H; Furihata T; Chiba K
Drug Metab Dispos; 2007 Jan; 35(1):72-8. PubMed ID: 17020955
[TBL] [Abstract][Full Text] [Related]
7. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of all-trans, 9-cis, and 13-cis isomers of retinal by purified isozymes of microsomal cytochrome P450 and mechanism-based inhibition of retinoid oxidation by citral.
Raner GM; Vaz AD; Coon MJ
Mol Pharmacol; 1996 Mar; 49(3):515-22. PubMed ID: 8643091
[TBL] [Abstract][Full Text] [Related]
10. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes.
Davies BJ; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Drug Metab Dispos; 2007 Jan; 35(1):128-38. PubMed ID: 17050648
[TBL] [Abstract][Full Text] [Related]
11. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs.
Leemann TD; Transon C; Bonnabry P; Dayer P
Drugs Exp Clin Res; 1993; 19(5):189-95. PubMed ID: 8174491
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate.
Yu C; Shin YG; Kosmeder JW; Pezzuto JM; van Breemen RB
Rapid Commun Mass Spectrom; 2003; 17(4):307-13. PubMed ID: 12569440
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
14. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers.
Meyer MR; Peters FT; Maurer HH
Drug Metab Dispos; 2008 Nov; 36(11):2345-54. PubMed ID: 18725511
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
16. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
[TBL] [Abstract][Full Text] [Related]
18. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
[TBL] [Abstract][Full Text] [Related]
19. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.
Huskey SW; Dean DC; Miller RR; Rasmusson GH; Chiu SH
Drug Metab Dispos; 1995 Oct; 23(10):1126-35. PubMed ID: 8654202
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane CL; Gill HS
J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]